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Abstract
Dutch laboratories are currently changing their breakpoint criteria from mostly Clinical Laboratory and Standards Institute (CLSI)
breakpoints to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. To evaluate the impact of these
changes, we studied antimicrobial resistance trends of Escherichia coli in blood specimens from January 2008 to January 2012 using CLSI
and EUCAST breakpoints and compared them with the antimicrobial susceptibility test (AST) interpretations reported by Dutch labo-
ratories participating in the Infectious Disease Surveillance Information System for Antibiotic Resistance (ISIS-AR). ISIS-AR collects AST
interpretations, including underlying minimal inhibitory concentrations (MICs) of routinely cultured bacterial species on a monthly basis
from Dutch laboratories. MICs of Etests or automated systems were reinterpreted according to the CLSI 2009 and EUCAST 2010
guidelines. Trends in non-susceptibility (i.e. intermediate resistant and resistant) over time were analysed by the Cochran–Armitage test
for trend. The effects of the change from CLSI to EUCAST breakpoints on non-susceptibility were small. There were no differences in
non-susceptibility to amoxicillin, amoxicillin/clavulanic acid, cefuroxim, gentamicin and co-trimoxazol and only small differences (1–1.5%)
for ciproﬂoxacin between AST interpretations by CLSI or EUCAST. However, for ceftazidime, and cefotaxime/ceftriaxone the propor-
tion of non-susceptibility was substantially higher when EUCAST breakpoints were used (2–3%). The effects on time trends of the
change in guidelines were limited, with only substantial differences for the oxymino-cephalosporins. Our study shows that the imple-
mentation of EUCAST breakpoints has a limited effect on the proportion of non-susceptible isolates and time trends in E. coli for most,
but not all, antimicrobial agents.
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Introduction
Antimicrobial surveillance is an important tool to monitor
the emergence and impact of resistant organisms. Addition-
ally, surveillance guides the empirical treatment choices of
clinicians [1]. The value of surveillance systems, especially
on-site laboratory based surveillance systems, depends on
the comparability of the applied methodology and the quality
assurance of the participating laboratories [2]. Standardiza-
tion of interpretation criteria and the use of internationally
accepted techniques for antimicrobial susceptibility testing
(AST) are therefore essential in surveillance systems based
on routinely generated data.
Both the Clinical and Laboratory Standards Institute
(CLSI) and the European Committee for Antimicrobial Sus-
ceptibility Testing (EUCAST) provide reference methods and
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breakpoints for classifying organisms as susceptible or resis-
tant to antimicrobial agents. EUCAST was initiated by the
European Society of Clinical Microbiology and Infectious Dis-
eases (ESCMID) to harmonize minimum inhibitory concen-
tration (MIC) breakpoints across Europe [3]. EUCAST in
general recommends lower MIC breakpoints deﬁning resis-
tance than CLSI and both EUCAST and CLSI have changed
their recommendations regarding the interpretation of sus-
ceptibility results for certain antimicrobial agents in Entero-
bacteriaceae over time (http://www.eucast.org) [4]; EUCAST
established susceptibility breakpoints for cefotaxime and ceft-
azidime at £1 mg/L in 2006/2007 [5], while CLSI changed the
breakpoint for cefotaxime from £8 to £1 mg/L and for ceft-
azidime from £8 to £4 mg/L in 2010 (Table 1) [4]. Another
important change in the CLSI 2010 guideline has been the
reporting of AST data for cephalosporins as found, irrespec-
tive of the presence of extended-spectrum-b-lactamases
(ESBLs), while previous editions recommended that ESBL-
producers should be reported as resistant to cephalosporins,
irrespective of the MIC [4,6]. A similar recommendation was
previously made by EUCAST in 2009 [7–9].
The adoption of new guidelines or changes in breakpoints
can have a substantial effect on the outcome and implications
of antimicrobial resistance surveillance [10]. Currently, labo-
ratories in Europe are encouraged to adopt EUCAST guide-
lines to facilitate comparability of AST results. In 2010,
Dutch laboratories started the implementation of EUCAST
guidelines for AST as recommended by the Dutch Society
for Medical Microbiology (NVMM). Previously, breakpoints
as recommended by CLSI or by the Dutch Breakpoint Com-
mittee (CRG) were used. To evaluate the impact of the
adoption of EUCAST on surveillance, we compared resis-
tance trends among Escherichia coli using CLSI and EUCAST
breakpoints and the AST results reported by Dutch labora-
tories participating in the Infectious Disease Surveillance
Information System for Antibiotic Resistance (ISIS-AR).
Material and Methods
ISIS-AR
ISIS-AR started in 2008 and is coordinated by the Centre for
Infectious Disease Control, National Institute for Public
Health and the Environment (RIVM), Bilthoven, the Nether-
lands. Currently, 29 laboratories, located in various regions
of the Netherlands, submit AST results (i.e. susceptible,
intermediate and resistant), including underlying MICs of
Etest or automated susceptibility testing systems and patient
data (i.e. age, gender, hospital department, specimen site), of
routinely cultured bacterial species on a monthly basis. Par-
ticipating laboratories serve tertiary referral centres, teaching
and community hospitals, outpatient clinics, long-term care
facilities, and general practitioners. ISIS-AR covers approxi-
mately 50% of the Dutch population and is, due to the wide
geographical distribution and diversity of sampling sites, con-
sidered representative for clinical AST data in the Nether-
lands. Data quality is assured by structural quality control,
which includes monthly feedback to the laboratories of abso-
lute numbers of isolates submitted, susceptibility patterns of
speciﬁc organisms such as Staphylococcus aureus and E. coli,
absolute number of highly resistant organisms, and isolates
with impossible and exceptional phenotypes according to the
EUCAST expert rules [8]. Exceptional phenotypes are
included in the ISIS-AR database only when conﬁrmed by a
secondary susceptibility test. In addition, most laboratories
are regularly audited by independent external experts of the
Dutch institute for the promotion of quality in laboratory
research and for the accreditation of laboratories in the
health care sector (CCKL [http://www.cckl.nl/]).
Isolates
We included all blood cultures with E. coli from January 2008
to January 2012. To avoid over-representation of multiple
TABLE 1. EUCAST 2010 (v1.1) and 2011 (v1.3) and CLSI 2009, 2010 and 2011 MIC clinical breakpoint recommendations in
mg/L (http://www.eucast.org) [4,6,11,13]
Antimicrobial agent
EUCAST 2010 EUCAST 2011 CLSI 2009 CLSI 2010 CLSI 2011
S£ R> S£ R> S£ R> S£ R> S£ R>
Amoxicillina 8 8 8 16 8 16 8 16
Amoxicillin/clavulanic acida 8 8 8 16 8 16 8 16
Cefuroxim 8 8 8 8 8 16 8 16 8 16
Ceftazidime 1 4 1 4 8 16 4 8 4 8
Ceftriaxone 1 2 1 2 8 32 1 2 1 2
Cefotaxime 1 2 1 2 8 32 1 2 1 2
Gentamicin 2 4 2 4 4 8 4 8 4 8
Ciproﬂoxacin 0.5 1 0.5 1 1 2 1 2 1 2
Co-trimoxazole 2 4 2 4 2 2 2 2 2 2
aFor this study a susceptibility MIC breakpoint of £8 was used, categorizing all wild-type Escherichia coli isolates as susceptible.
CMI van der Bij et al. Impact of changes in breakpoints on surveillance E467
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E466–E472
isolates from individual patients we only included the ﬁrst
isolate per patient per year. For all isolates, MICs for amoxi-
cillin or ampicillin (AMO), amoxicillin/clavulanic acid (AMC),
cefuroxim (CFX), ceftazidime (CAZ), cefotaxime (CTX), cef-
triaxone (CRO), gentamicin (GEN), ciproﬂoxacin (CIP) and
co-trimoxazole (SXT) were reinterpreted as susceptible or
non-susceptible (i.e. intermediate susceptible or resistant)
using the CLSI 2009 and the EUCAST 2010 (v1.1) break-
points (Table 1) [6,11]. MICs from Etests were given priority
over MICs from automated systems. AST data for CRO and
CTX were combined (i.e. if an isolate was non-susceptible to
either CRO or CTX, the isolate was considered to be non-
susceptible).
Statistical analysis
We determined the proportion of isolates non-susceptible as
recommended for surveillance purposes by CLSI [12], for
the AST interpretations reported by the laboratories and for
the MIC reinterpretations according to the CLSI 2009 and
EUCAST 2010 breakpoints. Additionally, we performed a
similar analysis in which laboratories were simulated to use
CLSI 2009 breakpoints in 2008 and 2009 and EUCAST 2010
breakpoints in 2010 and 2011, providing information on the
effect of the adoption of EUCAST guidelines on antimicrobial
resistance (i.e. guideline switch). Trends over time were anal-
ysed by the Cochran–Armitage test for trend using SAS soft-
ware version 9.2 (SAS Institute Inc., Cary, NC, USA).
Differences between AST results using CLSI 2009 break-
points and EUCAST 2010 breakpoints for each antimicrobial
agent were determined by calculating the proportion of iso-
lates that were differently interpreted (i.e. susceptible vs.
non-susceptible) by the two test methods. For analysis pur-
poses, isolates that were interpreted as susceptible by CLSI
breakpoints but non-susceptible by EUCAST breakpoints
were given the value 1, and isolates that were interpreted to
be similar were given the value 0. Subsequently, we used the
Cochran–Armitage test for trend to evaluate the change in
the proportion of isolates differently interpreted over time.
A signiﬁcant increasing trend will suggest that isolates are sig-
niﬁcantly more often interpreted as non-susceptible over
time when using EUCAST breakpoints in comparison to CLSI
breakpoints (i.e. a signiﬁcant time trend towards more resis-
tance with EUCAST). Furthermore, we performed a similar
analysis for AST results by the guideline switch (i.e. CLSI
2009 to EUCAST 2010) and AST results reported by the
laboratories to evaluate the impact of the implementation of
EUCAST breakpoints on reported resistance levels. Finally,
the same analysis was performed for AST results by
EUCAST 2010 breakpoints and AST results reported by
Dutch laboratories to evaluate the reliability of a surveillance
system based on on-site laboratory AST interpretations. For
the last two analyses, isolates that were interpreted as non-
susceptible by CLSI/EUCAST breakpoints but susceptible by
the laboratory were given the value 1, isolates that were
interpreted to be similar were given the value 0, and isolates
that were interpreted as susceptible by CLSI/EUCAST break-
points but non-susceptible by the laboratory were given the
value )1. We deﬁned statistical signiﬁcance as p < 0.05.
Results
A total of 17 486 E. coli isolates were included. Reinterpreta-
tion of MIC values with CLSI and EUCAST breakpoints was
possible for AMC, CIP, GEN and SXT in 90% of isolates
(Table 2). For all other agents reinterpretation of MIC values
was possible for over 70% of isolates and was similar for
CLSI and EUCAST breakpoints. Not all participating labora-
tories submit MIC values for all agents, explaining most of
the isolates for which an MIC reinterpretation was not possi-
ble (Table 2). We therefore assumed that these isolates
were randomly distributed among susceptible and non-sus-
ceptible phenotypes, limiting selection bias.
Time trends
Except for CIP and SXT, the proportion of non-susceptible
isolates was highest when the AST interpretations reported
by the laboratories were used (Table 3). For all four AST
interpretation methods, there was no increase in the pro-
portion of isolates non-susceptible to AMO and SXT over
time, while the proportion of isolates non-susceptible to
CFX, CAZ, GEN and CIP increased signiﬁcantly since January
2008 (Table 3). For AMC the proportion of non-susceptible
isolates showed a signiﬁcant increase from 22.2% in 2008
to 25.8% in 2011 for the AST results reported by the
TABLE 2. Percentage of E. coli isolates in blood specimens
with data available on antimicrobial susceptibility test inter-
pretations reported by laboratories (SIR), MIC value and
with a MIC value that was reinterpretable by CLSI 2009 and
EUCAST 2010 (v1.1) breakpoints, the Netherlands 2008–
2012 (n = 17 486)
Antimicrobial agent
SIR
%
MIC
value %
CLSI
2009 %
EUCAST
2010 %
Amoxicillin 99 81 81 81
Amoxicillin/clavulanic acid 98 90 90 90
Cefuroxim 93 85 85 85
Ceftazidime 96 87 87 86
Ceftriaxone/Cefotaxime 95 87 87 87
Gentamicin 98 90 90 90
Ciproﬂoxacin 99 90 90 90
Co-trimoxazole 99 90 90 90
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laboratories. However, there was no increase in AMC non-
susceptibility when MICs were reinterpreted according to
the EUCAST and CLSI breakpoints (19.8% in 2008 and
19.3% in 2011). For CRO/CTX there was a signiﬁcant
increase in non-susceptibility over time when analysing AST
interpretations according to the laboratories and EUCAST
2010 breakpoints, and when switching in 2010 from CLSI
2009 to EUCAST 2010 breakpoints, while there was no
increase when analysing AST interpretations according to
CLSI 2009 breakpoints (Table 3).
To evaluate the effect of the application of a speciﬁc
guideline (i.e. CLSI or EUCAST) on antimicrobial resistance
trends, we determined the proportion of isolates differently
interpreted for each antimicrobial agent by EUCAST 2010
and CLSI 2009 breakpoints as described in the methods sec-
tion. This analysis showed a signiﬁcant increase over time in
the proportion of isolates that were interpreted as non-sus-
ceptible to CAZ and CRO/CTX with EUCAST breakpoints,
but that were interpreted as susceptible with CLSI break-
points. This ﬁnding suggests a larger rise in non-susceptibility
to the oxymino-cephalosporins when the EUCAST break-
points are used.
Furthermore, to assess the impact of a guideline change
on resistance trends, we determined the proportion of iso-
lates differently interpreted by the simulated guideline switch
and the AST results of the laboratories. Surprisingly, despite
the fact that the same susceptibility breakpoints are used by
CLSI and EUCAST for AMO and AMC (Table 1), there was
a signiﬁcant increase over time in the proportion of isolates
that were interpreted as non-susceptible by the laboratories,
but were interpreted as susceptible by the simulated guide-
line switch, suggesting a larger rise in non-susceptibility when
laboratory AST results are used. A similar ﬁnding was found
for GEN. For CFX, the susceptibility breakpoints for EU-
CAST and CLSI are the same as well. However, there was a
signiﬁcant decrease over time in the proportion of isolates
that were interpreted as non-susceptible by the laboratories,
but were interpreted as susceptible by the simulated guide-
line switch, suggesting a larger rise in non-susceptibility to
CFX with the simulated guideline switch. A similar ﬁnding
was found for CIP.
Finally, we determined the proportion of isolates differ-
ently interpreted by EUCAST 2010 breakpoints and the AST
results of the laboratories to evaluate the reliability of a
TABLE 3. Percentage of non-susceptible (NS) E. coli isolates (n = 17 486) in blood specimens per year according to the antimi-
crobial susceptibility test interpretations reported by laboratories (SIR), CLSI 2009 breakpoints (CLSI 2009) and EUCAST
2010 (v1.1) breakpoints (EUCAST 2010) and according to the use of CLSI 2009 breakpoints in 2008 and 2009 and EUCAST
2010 breakpoints in 2010 and 2011 (CLSI/EUCAST), the Netherlands 2008–2012
Antimicrobial agent % NS 2008 % NS 2009 % NS 2010 % NS 2011 p-value trendb
Amoxicillin
EUCAST 2010a 48.0 47.3 47.8 47.8 0.99
SIR 48.8 48.1 49.0 50.6 0.09
Amoxicillin/clavulanic acid
EUCAST 2010a 19.8 18.4 22.8 19.3 0.34
SIR 22.2 21.9 26.5 25.8 <0.001
Cefuroxim
EUCAST 2010a 9.2 9.5 10.8 11.4 <0.001
SIR 10.5 10.9 12.6 12.0 0.02
Ceftazidime
CLSI 2009 1.7 1.8 2.4 2.2 0.05
EUCAST 2010 3.5 3.3 4.3 4.7 <0.001
CLSI/EUCAST 1.7 1.8 4.3 4.7 <0.001
SIR 3.6 3.9 4.7 5.4 <0.001
Cefotaxime/Ceftriaxone
CLSI 2009 3.0 3.4 3.6 2.8 0.84
EUCAST 2010 3.5 4.0 5.3 5.9 <0.001
CLSI/EUCAST 3.0 3.4 5.3 5.9 <0.001
SIR 3.7 4.1 5.1 5.7 <0.001
Gentamicin
CLSI 2009 4.1 4.7 5.0 6.1 <0.001
EUCAST 2010 4.8 5.9 6.2 6.6 <0.001
CLSI/EUCAST 4.1 4.7 6.2 6.6 <0.001
SIR 4.7 6.6 6.9 7.5 <0.001
Ciproﬂoxacin
CLSI 2009 12.4 12.6 13.9 14.0 0.01
EUCAST 2010 13.8 14.2 15.1 15.5 0.02
CLSI/EUCAST 12.4 12.6 15.1 15.5 <0.001
SIR 12.5 12.7 14.2 14.3 0.006
Co-trimoxazole
EUCAST 2010a 30.7 28.9 28.7 30.5 0.99
SIR 30.6 28.8 28.5 29.9 0.99
aIn the case of the same susceptibility breakpoint for CLSI 2009 and EUCAST 2010, results for EUCAST 2010 are presented because the percentage of isolates that are non-
susceptible will be the same irrespective of the guideline used.
bCochran–Armitage test for trend.
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surveillance system based on on-site laboratory AST inter-
pretations in comparison to a surveillance system based on
MICs. Results found were the same as described above for
the simulated guideline switch with respect to AMO, AMC
and CFX, suggesting a larger rise in non-susceptibility to
AMO and AMC when laboratory AST interpretations are
used, and a larger rise in non-susceptibility to CFX when EU-
CAST breakpoints are used.
Discussion
In 2011, 45% of the laboratories participating in ISIS-AR used
EUCAST breakpoints for AST vs. none in 2008. One of the
concerns regarding the change from CLSI to EUCAST rec-
ommendations is the anticipated increase in resistance
because EUCAST recommends lower MIC breakpoints deﬁn-
ing resistance for most antimicrobial agents than CLSI
(Table 1) [13]. However, the effects of the implementation
of EUCAST breakpoints on antimicrobial non-susceptibility in
E. coli were small based on AST results of Dutch laborato-
ries. For most antimicrobial agents there were either no dif-
ferences in non-susceptibility (AMO, AMC, CFX, GEN and
SXT) or only small differences (CIP). For CAZ and CRO/
CTX, the proportion of non-susceptibility was, however,
substantially higher when EUCAST breakpoints were used
(2–3%) and there was a substantial difference in resistance
trends for the oxymino-cephalosporins when CLSI or EU-
CAST breakpoints were used. Additionally, there was a sig-
niﬁcant increase in the proportion of isolates over time that
were interpreted as non-susceptible to CAZ and CRO/CTX
with EUCAST 2010 breakpoints, but that were interpreted
as susceptible with CLSI 2009 breakpoints, providing evi-
dence for a rise of isolates with an MIC between 1 and 8
mg/L and a true increase in resistance only detected with
the lower MIC susceptibility breakpoints used by EUCAST. It
is important to mention that CLSI has lowered its suscepti-
bility breakpoints for the oxymino-cephalosporins in 2010
and that for CRO and CTX the breakpoints currently used
by CLSI and EUCAST are the same (Table 1) [4].
Despite the limited effects of the adoption of EUCAST
breakpoints on non-susceptibility and surveillance, there is a
potential effect on resistance levels, complicating therapy
choices, due to the larger variations in resistance breakpoints
than in susceptibility breakpoints between CLSI and EUCAST.
These variations are explained by the intermediate category
used by CLSI for certain agents, such as AMC and CFX,
which is not used by EUCAST. For instance, resistance to
AMC was 6.5% in 2011 when using CLSI breakpoints, com-
pared with 19.3% when using EUCAST breakpoints. For CFX
these numbers were 5.8% and 11.4%. For AMC there is an
additional difference between CLSI and EUCAST; EUCAST
recommends a ﬁxed concentration of clavulanate of 2 mg/L,
while CLSI recommends a ﬁxed amoxicillin/clavulanate ratio
(2:1) for susceptibility testing, which might inﬂuence resis-
tance levels as well. Currently, most (25/29) of the laborato-
ries participating in ISIS-AR use the VITEK automated system
(bioMe´rieux Vitek Systems Inc., Hazelwood, MO, USA) and
the ﬁxed amoxicillin/clavulanate ratio for susceptibility testing.
Interestingly, the proportion of non-susceptible isolates
was highest for the AST results of the Dutch laboratories.
Additionally, there were substantially different time trends
between AST interpretations of laboratories and AST rein-
terpretations by EUCAST breakpoints, in particular for AMC
and CFX. EUCAST leaves it to the user to categorize wild-
type E. coli as susceptible or intermediate for AMC depend-
ing on dosing, route of administration and whether the infec-
tion is systemic or affects the urinary tract only [11]. For
this study we decided to categorize all wild-type E. coli (MIC
£8 mg/L) as susceptible to AMC. The categorization of wild-
type E. coli as intermediate will dramatically increase non-sus-
ceptibility levels when changing from CLSI to EUCAST
breakpoints and explains approximately half of the higher
proportion of non-susceptible isolates when AST results of
the laboratories were used. For CFX, CLSI and EUCAST use
the same breakpoint. Differences in non-susceptibility and
time trends can therefore not be explained by the use of dif-
ferent guidelines and suggest the use of other MIC suscepti-
bility breakpoints than the ones recommended by CLSI or
EUCAST in Dutch laboratories. Other explanations for the
differences found between AST results of the laboratories
and AST reinterpretations with CLSI and/or EUCAST break-
points are the use of expert-rules by automated testing
systems, such as the editing of the AST results for certain
beta-lactams if an ESBL-producing enzyme is present
(explaining approximately 30% of the differences in AST
interpretations), editing by the local clinical microbiologist,
or errors in the laboratory information system.
We did not present data on imipenem, because no resis-
tance was found. Furthermore, no data on piperacillin/tazo-
bactam (PTZ) was presented because the signiﬁcant >4%
increase in PTZ non-susceptibility for all four AST interpre-
tations that we found from 2009 to 2010 is likely to be
explained by the switch in the reference method to validate
the susceptibility results of the VITEK 2 automated system
(bioMe´rieux Vitek Systems Inc., Hazelwood, MO, USA).
Before 2009 VITEK 2 susceptibility data were validated
against agar dilution, while since 2009 VITEK 2 susceptibility
data have been validated against broth micro-dilution. In the
four laboratories participating in ISIS-AR that are using the
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Phoenix automated system (BD, Franklin Lakes, NJ, USA) no
signiﬁcant increase was found in PTZ non-susceptibility.
The differences found between laboratory AST results and
the reinterpretations of MICs by CLSI or EUCAST break-
points demonstrate the importance of a uniform AST meth-
odology for on-site surveillance systems. In a recent study by
the European Antimicrobial Resistance Surveillance Network
(EARS-net), resistance was determined by the guidelines
used by the reporting countries because the MIC values
were not systematically available for all participating labora-
tories [14]. Other surveillance systems, such as SENTRY and
MYSTIC surveillance programs, use central laboratories for
conﬁrmation of speciation and susceptibility testing [15,16].
Centralized testing is a preferred method in surveillance due
to the minimization of variation in techniques and control of
the organism collection [2]. However, this is an expensive
way of surveillance because all isolates have to be retested,
which militates against the use of routinely generated data. A
network in which participating laboratories are using the
same AST methodology is a good alternative and compro-
mise between feasibility and accuracy.
In this study, we used routinely collected MICs of Etests
and automated testing systems to study resistance trends.
Bias introduced by different breakpoints was therefore
avoided. The results show that the implementation of EU-
CAST will have a limited effect on the proportion of non-
susceptible isolates and time trends in E. coli for most, but
not all, antimicrobial agents. Furthermore, our study shows
that the reporting of MIC values is important for on-site lab-
oratory-based surveillance systems and illustrates the impor-
tance of a uniform methodology for routine susceptibility
data to effectively monitor antimicrobial resistance. The fur-
ther implementation of EUCAST guidelines in Europe will
therefore optimize comparability of routine AST results and
will improve the reliability of current surveillance systems.
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